-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Faeth Therapeutics, Maintains $56 Price Target

Benzinga·11/16/2026 16:04:03
Needham analyst Gil Blum reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $56 price target.